{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:56:21Z","timestamp":1793825781479,"version":"4.6.1"},"reference-count":62,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have transformed the therapeutic landscape for several malignancies, but their efficacy in unresectable pancreatic adenocarcinoma remains uncertain. This systematic review aimed to evaluate the effectiveness and safety of ICIs in this context, focusing on overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and toxicity. A comprehensive search of MEDLINE, EMBASE, CENTRAL, and Scopus identified 34 eligible studies, including randomized controlled trials and observational cohorts. Quantitative synthesis involved 21 studies comprising 937 patients, with additional qualitative analyses on biomarker-driven subgroups and early-phase trials. The median OS across studies was 8.65 months, while the median PFS was 2.55 months. The ORR and DCR were 16.2% and 50.3%, respectively, with grade \u22653 treatment-related adverse events occurring in 22% of patients. Promising outcomes were observed in MSI-H\/dMMR populations, although these represented only 1\u20132% of cases. Combination strategies with chemotherapy demonstrated synergistic potential but lacked definitive evidence due to heterogeneity and the absence of phase III trials. ICIs showed a manageable toxicity profile, highlighting their feasibility in selected patients. Future research should focus on overcoming tumor microenvironment barriers and identifying biomarkers to optimize responsiveness and expand the applicability of ICIs in pancreatic cancer.<\/jats:p>","DOI":"10.3390\/ijms26062620","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T07:02:16Z","timestamp":1741935736000},"page":"2620","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["State of the Art of Immune Checkpoint Inhibitors in Unresectable Pancreatic Cancer: A Comprehensive Systematic Review"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2559-7558","authenticated-orcid":false,"given":"Elena","family":"Orlandi","sequence":"first","affiliation":[{"name":"Department of Oncology-Hematology, Azienda USL of Piacenza, 29121 Piacenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8855-8919","authenticated-orcid":false,"given":"Massimo","family":"Guasconi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, 43121 Parma, Italy"},{"name":"Department of Health Professions Management, Azienda USL of Piacenza, 29121 Piacenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7725-635X","authenticated-orcid":false,"given":"Andrea","family":"Romboli","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Azienda USL of Piacenza, 29121 Piacenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8335-3941","authenticated-orcid":false,"given":"Mario","family":"Giuffrida","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Azienda USL of Piacenza, 29121 Piacenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5217-3859","authenticated-orcid":false,"given":"Ilaria","family":"Toscani","sequence":"additional","affiliation":[{"name":"Department of Oncology-Hematology, Azienda USL of Piacenza, 29121 Piacenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Anselmi","sequence":"additional","affiliation":[{"name":"Department of Oncology-Hematology, Azienda USL of Piacenza, 29121 Piacenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Porzio","sequence":"additional","affiliation":[{"name":"Department of Oncology-Hematology, Azienda USL of Piacenza, 29121 Piacenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Madaro","sequence":"additional","affiliation":[{"name":"Department of Oncology-Hematology, Azienda USL of Piacenza, 29121 Piacenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0578-0870","authenticated-orcid":false,"given":"Stefano","family":"Vecchia","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Azienda USL of Piacenza, 29121 Piacenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2119-775X","authenticated-orcid":false,"given":"Chiara","family":"Citterio","sequence":"additional","affiliation":[{"name":"Department of Oncology-Hematology, Azienda USL of Piacenza, 29121 Piacenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Jooste, V., Bengrine-Lefevre, L., Manfredi, S., Quipourt, V., Grosclaude, P., Facy, O., Lepage, C., Ghiringhelli, F., and Bouvier, A.-M. (2022). Management and Outcomes of Pancreatic Cancer in French Real-World Clinical Practice. Cancers, 14.","DOI":"10.3390\/cancers14071675"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased Survival in Pancreatic Cancer with Nab-Paclitaxel Plus Gemcitabine","volume":"369","author":"Ervin","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in Survival and Clinical Benefit with Gemcitabine as First-Line Therapy for Patients with Advanced Pancreas Cancer: A Randomized Trial","volume":"15","author":"Burris","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal Irinotecan with Fluorouracil and Folinic Acid in Metastatic Pancreatic Cancer after Previous Gemcitabine-Based Therapy (NAPOLI-1): A Global, Randomised, Open-Label, Phase 3 Trial","volume":"387","author":"Li","year":"2016","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1200\/JCO.2002.20.1.160","article-title":"Phase II Study of Oral Capecitabine in Patients With Advanced or Metastatic Pancreatic Cancer","volume":"20","author":"Cartwright","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/annonc\/mdt166","article-title":"Second-Line Treatment in Advanced Pancreatic Cancer: A Comprehensive Analysis of Published Clinical Trials","volume":"24","author":"Rahma","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.21037\/cco.2017.06.04","article-title":"Rational Combinations of Immunotherapy for Pancreatic Ductal Adenocarcinoma","volume":"6","author":"Blair","year":"2017","journal-title":"Chin. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Cheng, D., Hu, J., Wu, X., Wang, B., Chen, R., Zhao, W., Fang, C., and Ji, M. (2023). PD-1 Blockade Combined with Gemcitabine Plus Nab-Paclitaxel Is Superior to Chemotherapy Alone in the Management of Unresectable Stage III\/IV Pancreatic Cancer: A Retrospective Real-World Study. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1281545"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients with Noncolorectal High Microsatellite Instability\/Mismatch Repair\u2013Deficient Cancer: Results from the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/gutjnl-2020-320726","article-title":"Comprehensive Characterisation of Pancreatic Ductal Adenocarcinoma with Microsatellite Instability: Histology, Molecular Pathology and Clinical Implications","volume":"70","author":"Luchini","year":"2021","journal-title":"Gut"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e003024","DOI":"10.1136\/jitc-2021-003024","article-title":"Defining Unique Clinical Hallmarks for Immune Checkpoint Inhibitor-Based Therapies","volume":"10","author":"Michielin","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_15","unstructured":"Wells, G., Shea, B., O\u2019Connell, D., Robertson, J., Peterson, J., Welch, V., Losos, M., and Tugwell, P. (2024, November 11). The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-Analysis. Available online: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"ref_16","unstructured":"(2025, January 29). NIH Study Quality Assessment Tools|NHLBI, NIH, Available online: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools."},{"key":"ref_17","first-page":"93","article-title":"How to Perform Meta-Analysis in R: A Simple yet Comprehensive Guide","volume":"1","author":"Shamim","year":"2023","journal-title":"Evid"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring Inconsistency in Meta-Analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1002\/sim.1221","article-title":"A Graphical Method for Exploring Heterogeneity in Meta-analyses: Application to a Meta-analysis of 65 Trials","volume":"21","author":"Baujat","year":"2002","journal-title":"Stat. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in Meta-Analysis Detected by a Simple, Graphical Test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"ref_21","first-page":"89","article-title":"A Nonparametric \u201cTrim and Fill\u201d Method of Accounting for Publication Bias in Meta-Analysis","volume":"95","author":"Duval","year":"2000","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/ije\/dyn065","article-title":"Sensitivity of Between-Study Heterogeneity in Meta-Analysis: Proposed Metrics and Empirical Evaluation","volume":"37","author":"Patsopoulos","year":"2008","journal-title":"Int. J. Epidemiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2147\/OTT.S427942","article-title":"Safety and Efficacy Analysis of PD-1 Inhibitors in Combination with Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer: A Real-World, Single-Center Study","volume":"16","author":"Chen","year":"2023","journal-title":"OncoTargets Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2143154","DOI":"10.1080\/21645515.2022.2143154","article-title":"Efficacy and Safety of Immune Checkpoint Inhibitors in Advanced Pancreatic Cancer: A Real World Study in Chinese Cohort","volume":"18","author":"Gong","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e006136","DOI":"10.1136\/jitc-2022-006136","article-title":"Phase Ib Open-Label, Multicenter Study of Pixatimod, an Activator of TLR9, in Combination with Nivolumab in Subjects with Microsatellite-Stable Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma and Other Solid Tumors","volume":"11","author":"Lemech","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00262-019-02452-3","article-title":"Immune Checkpoint Inhibitors Combined with Chemotherapy for the Treatment of Advanced Pancreatic Cancer Patients","volume":"69","author":"Ma","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e002068","DOI":"10.1136\/jitc-2020-002068","article-title":"Safety and Activity of the TGF\u03b2 Receptor I Kinase Inhibitor Galunisertib Plus the Anti-PD-L1 Antibody Durvalumab in Metastatic Pancreatic Cancer","volume":"9","author":"Melisi","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(22)00369-2","article-title":"Niraparib Plus Nivolumab or Niraparib Plus Ipilimumab in Patients with Platinum-Sensitive Advanced Pancreatic Cancer: A Randomised, Phase 1b\/2 Trial","volume":"23","author":"Reiss","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1038\/s41467-022-32591-8","article-title":"The CCTG PA.7 Phase II Trial of Gemcitabine and Nab-Paclitaxel with or without Durvalumab and Tremelimumab as Initial Therapy in Metastatic Pancreatic Ductal Adenocarcinoma","volume":"13","author":"Renouf","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J. Immunother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.2147\/TCRM.S173041","article-title":"Clinical Observation of Immune Checkpoint Inhibitors in the Treatment of Advanced Pancreatic Cancer: A Real-World Study in Chinese Cohort","volume":"14","author":"Sun","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1158\/1078-0432.CCR-19-3978","article-title":"Evaluation of Cyclophosphamide\/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer","volume":"26","author":"Tsujikawa","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00262-024-03744-z","article-title":"Hypofractionated Radiotherapy Plus PD-1 Antibody and SOX Chemotherapy as Second-Line Therapy in Metastatic Pancreatic Cancer: A Single-Arm, Phase II Clinical Trial","volume":"73","author":"Wang","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1158\/1078-0432.CCR-19-3624","article-title":"Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma","volume":"26","author":"Xie","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00262-024-03821-3","article-title":"Adding-on Nivolumab to Chemotherapy-Stabilized Patients Is Associated with Improved Survival in Advanced Pancreatic Ductal Adenocarcinoma","volume":"73","author":"Yang","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2147\/CMAR.S349442","article-title":"The Efficacy and Safety of PD-1 Inhibitors Combined with Nab-Paclitaxel Plus Gemcitabine versus Nab-Paclitaxel Plus Gemcitabine in the First-Line Treatment of Advanced Pancreatic Cancer: A Retrospective Monocentric Study","volume":"14","author":"Zhang","year":"2022","journal-title":"Cancer Manag. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/s41591-020-0880-x","article-title":"BL-8040, a CXCR4 Antagonist, in Combination with Pembrolizumab and Chemotherapy for Pancreatic Cancer: The COMBAT Trial","volume":"26","author":"Bockorny","year":"2020","journal-title":"Nat. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00423-021-02321-7","article-title":"Nab-Paclitaxel Plus S-1 with or Without PD-1 Inhibitor in Pancreatic Ductal Adenocarcinoma with Only Hepatic Metastases: A Retrospective Cohort Study","volume":"407","author":"Liu","year":"2022","journal-title":"Langenbecks Arch. Surg."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"112635","DOI":"10.1016\/j.intimp.2024.112635","article-title":"Efficacy and Safety of Gemcitabine\/Nab-Paclitaxel Combined with Anlotinib and PD-1 Inhibitors as a First-Line Treatment for Advanced Pancreatic Cancer","volume":"139","author":"Liu","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/s43018-021-00269-7","article-title":"Radiation Therapy Enhances Immunotherapy Response in Microsatellite Stable Colorectal and Pancreatic Adenocarcinoma in a Phase II Trial","volume":"2","author":"Parikh","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1158\/1078-0432.CCR-21-2781","article-title":"Mogamulizumab in Combination with Nivolumab in a Phase I\/II Study of Patients with Locally Advanced or Metastatic Solid Tumors","volume":"28","author":"Hong","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e007883","DOI":"10.1136\/jitc-2023-007883","article-title":"Nivolumab Monotherapy or Combination with Ipilimumab with or without Cobimetinib in Previously Treated Patients with Pancreatic Adenocarcinoma (CheckMate 032)","volume":"12","author":"Callahan","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1158\/1078-0432.CCR-20-4746","article-title":"Phase I\/Ib Clinical Trial of Sabatolimab, an Anti\u2013TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti\u2013PD-1 Antibody, in Advanced Solid Tumors","volume":"27","author":"Curigliano","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1158\/1078-0432.CCR-20-4118","article-title":"A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies","volume":"27","author":"Hegde","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00280-020-04161-6","article-title":"Dose Exploration Results from Phase 1 Study of Cemiplimab, a Human Monoclonal Programmed Death (PD)-1 Antibody, in Japanese Patients with Advanced Malignancies","volume":"87","author":"Kitano","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-21-1345","article-title":"Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors","volume":"12","author":"Muik","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/cncr.34512","article-title":"Phase 1\/2 Study of Epacadostat in Combination with Durvalumab in Patients with Metastatic Solid Tumors","volume":"129","author":"Naing","year":"2023","journal-title":"Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1158\/1078-0432.CCR-20-2886","article-title":"Phase I Study of MK-4166, an Anti-Human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors","volume":"27","author":"Papadopoulos","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1158\/1078-0432.CCR-23-2893","article-title":"Xevinapant Combined with Pembrolizumab in Patients with Advanced, Pretreated, Colorectal and Pancreatic Cancer: Results of the Phase Ib\/II CATRIPCA Trial","volume":"30","author":"Voisin","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e009262","DOI":"10.1136\/jitc-2024-009262","article-title":"Phase I Study of the Safety and Clinical Activity of the Interleukin-8 Inhibitor AMY109 Combined with Atezolizumab in Patients with Advanced Solid Cancers","volume":"12","author":"Yamamoto","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1158\/1078-0432.CCR-20-0328","article-title":"Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study","volume":"26","author":"Zamarin","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1007\/s00262-022-03160-1","article-title":"Penpulimab, an Anti-PD1 IgG1 Antibody in the Treatment of Advanced or Metastatic Upper Gastrointestinal Cancers","volume":"71","author":"Zheng","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejca.2023.04.012","article-title":"Efficacy of Immune Checkpoint Inhibitors in Microsatellite Unstable\/Mismatch Repair-Deficient Advanced Pancreatic Adenocarcinoma: An AGEO European Cohort","volume":"188","author":"Sayah","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e2341165","DOI":"10.1001\/jamanetworkopen.2023.41165","article-title":"Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients with Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial","volume":"6","author":"Berton","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e008409","DOI":"10.1136\/jitc-2023-008409","article-title":"Modified FOLFOX6 Plus Bevacizumab with and Without Nivolumab for First-Line Treatment of Metastatic Colorectal Cancer: Phase 2 Results from the CheckMate 9X8 Randomized Clinical Trial","volume":"12","author":"Lenz","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_57","unstructured":"National Comprehensive Cancer Network (2025, January 29). Pancreatic Adenocarcinoma NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Version 1. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1457."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Wang, T., Denman, D., Bacot, S.M., and Feldman, G.M. (2022). Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy. Biomedicines, 10.","DOI":"10.3390\/biomedicines10051181"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"17562848221117638","DOI":"10.1177\/17562848221117638","article-title":"Expression of PD-L1 as a Predictive Marker of Sensitivity to Immune Checkpoint Inhibitors in Patients with Advanced Biliary Tract Cancer","volume":"15","author":"Kim","year":"2022","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e15141","DOI":"10.1200\/JCO.2023.41.16_suppl.e15141","article-title":"Programmed Cell Death Ligand 1 (PD-L1) Expression Landscape and Its Relationship with Tumor Mutational Burden (TMB) in a Community-Based Cancer Center Patient Population in Rural Central Nebraska","volume":"41","author":"Copur","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1039\/D0BM00916D","article-title":"Co-Inhibition of the TGF-\u03b2 Pathway and the PD-L1 Checkpoint by pH-Responsive Clustered Nanoparticles for Pancreatic Cancer Microenvironment Regulation and Anti-Tumor Immunotherapy","volume":"8","author":"Wang","year":"2020","journal-title":"Biomater. Sci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"9881","DOI":"10.1021\/acsnano.8b02481","article-title":"Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer","volume":"12","author":"Zhao","year":"2018","journal-title":"ACS Nano"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/6\/2620\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:53:39Z","timestamp":1760028819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/6\/2620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":62,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["ijms26062620"],"URL":"https:\/\/doi.org\/10.3390\/ijms26062620","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]}}}